For instance, TRIM22 has been shown to inhibit osteosarcoma progression by activating the ROS/AMPK/mTOR/autophagy signaling pathway through weakening Nrf2 protein stability (Liu et al., 2022). The gene discussed is MTOR; the disease is osteosarcoma.